Back to Search Start Over

Vaccine preventable diseases surveillance in Nepal: How much does it cost?

Authors :
Sudhir Joshi
Pasang Rai
Xiao Xian Huang
Jhalak Sharma Gautam
Binod Prasad Gupta
Anindya Sekhar Bose
Bhim Singh Tinkari
Adam L. Cohen
Jos Vandelaer
Minal K. Patel
Source :
Vaccine
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Assessing the cost of vaccine preventable diseases (VPD) surveillance is becoming more important in the context of the Global Polio Eradication Initiative (GPEI) funding transition, since GPEI support to polio surveillance helped the incremental building of VPD surveillance systems in many countries, including low income countries such as Nepal. However, there is limited knowledge on the cost of conducting VPD surveillance, especially the national cost for surveillance of multiple vaccine-preventable diseases. The current study sought to calculate the economic and financial costs of Nepal’s comprehensive VPD surveillance systems from July 2016 to July 2017. At thecentral level, all surveillance units were included in the sample. At sub-national level, a purposive sampling strategy was used to select a representative sample from locations involved in conducting surveillance. The sub-national sample costs were extrapolated to the nationwide VPD surveillance system. Nepal’s total annual economic cost of VPD surveillance was USD 4.81 million or USD 0.18 per capita, while the total financial cost was USD 4.38 million or USD 0.16 per capita. Government expenditures accounted for 56% of the total economic cost, and World Health Organization accounting for 44%. The biggest cost driver was personnel accounting for 51% of the total economic cost. WHO supported trained surveillance personnel through donor funding, mainly from Global Polio Eradication Initiative. As a polio transition priority country, Nepal will need to make strategic choices to fully self-finance or seek full donor support or a mixed-financing model as polio program funding diminishes.

Details

ISSN :
0264410X
Volume :
39
Database :
OpenAIRE
Journal :
Vaccine
Accession number :
edsair.doi.dedup.....e6f390588bb5797dea8f1297496ca163
Full Text :
https://doi.org/10.1016/j.vaccine.2021.07.038